JNJNYSEPharmaceutical PreparationsFiscal year ends January 3

JOHNSON & JOHNSON

Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026

$253.79−1.77 (-0.69%)

Close on Oct 19, 2026

Market cap: $619.27B
P/E (TTM): 29.4
Dividend yield: 2.03%

JOHNSON & JOHNSON income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-28	FY 2024 2024-12-29	FY 2023 2023-12-31	FY 2022 2023-01-01	FY 2021 2022-01-02	FY 2020 2021-01-03	FY 2019 2019-12-29	FY 2018 2018-12-30	FY 2017 2017-12-31	FY 2016 2017-01-01	FY 2015 2016-01-03	FY 2014 2014-12-28	FY 2013 2013-12-29	FY 2012 2012-12-30	FY 2011 2012-01-01	FY 2010 2011-01-02	FY 2009 2010-01-03	FY 2008 2008-12-28	FY 2007 2007-12-30
Revenue	94,193	88,821	85,159	79,990	78,740	82,584	82,059	81,581	76,450	71,890	70,074	74,331	71,312	67,224	65,030	61,587	61,897	63,747	61,095
Cost of Revenue	30,256	27,471	26,553	24,596	23,402	28,427	27,556	27,091	25,439	21,789	21,536	22,746	22,342	21,658	20,360	18,792	18,447	18,511	17,751
Gross Profit	63,937	61,350	58,606	55,394	55,338	54,157	54,503	54,490	51,011	50,101	48,538	51,585	48,970	45,566	44,670	42,795	43,450	45,236	43,344
Research & Development	109	1,841	483	0	0	12,159	11,355	10,775	10,594	9,143	9,046	8,494	8,183	7,665	7,548	6,844	6,986	7,577	7,680
Selling, General & Admin	23,676	22,869	21,512	20,246	20,118	22,084	22,178	22,540	21,520	20,067	21,203	21,954	21,830	20,869	20,969	19,424	19,801	21,490	20,451
Advertising Expenses	1,600	600	500	700	1,200	2,100	2,200	2,600	2,500	2,400	2,500	2,600	2,500	2,300	2,600	2,500	2,400	2,900	–
Operating Income	–	–	–	–	–	–	–	–	–	–	–	21,590	16,412	14,955	13,765	17,700	16,582	–	–
Interest Expense	971	755	772	276	183	201	318	1,005	934	726	552	533	482	532	571	455	451	435	296
Interest & Investment Income	1,056	1,332	1,261	490	53	111	357	611	385	368	128	67	74	64	91	107	90	361	452
Other Non-Operating Income	7,209	-4,694	-6,634	-810	-526	-2,899	-2,525	-1,405	42	-210	2,064	70	-2,498	-1,626	-2,743	768	526	1,015	-534
Merger & Restructuring Charges	228	234	489	275	209	247	266	251	309	491	509	0	0	0	569	0	1,073	0	745
Asset Impairment Charges	204	405	1,295	1,216	989	233	1,096	1,258	795	283	624	410	739	2,131	160	0	–	–	–
Gain (Loss) on Investments	–	-400	-400	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	1,200	1,300	600	2,600	2,400	100	900	1,000	–	–	536	–
Legal Settlements	–	–	100	–	–	–	–	–	–	–	-141	-1,253	-2,276	-1,218	-3,310	966	–	379	–
Pretax Income	32,581	16,687	15,062	19,359	19,178	16,497	17,328	17,999	17,673	19,803	19,196	20,563	15,471	13,775	12,361	16,947	15,755	16,929	13,283
Income Tax Expense	5,777	2,621	1,736	2,989	1,377	1,783	2,209	2,702	16,373	3,263	3,787	4,240	1,640	3,261	2,689	3,613	3,489	3,980	2,707
Income from Continuing Operations	26,804	14,066	13,326	16,370	17,801	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Income from Discontinued Operations	0	0	21,827	1,571	3,077	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	–	–	–	–	–	16,323	13,831	10,514	9,672	13,334	12,266	12,949	10,576
Minority Interest in Earnings	–	–	–	–	–	–	–	–	–	–	–	0	0	-339	0	0	–	–	–
Net Income	26,804	14,066	35,153	17,941	20,878	14,714	15,119	15,297	1,300	16,540	15,409	16,323	13,831	10,853	9,672	13,334	–	–	–
EPS (Basic)(per share)	11.13	5.84	13.88	6.83	7.93	5.59	5.72	5.70	0.48	6.04	5.56	5.80	4.92	3.94	3.54	4.85	4.45	4.62	3.67
EPS (Diluted)(per share)	11.03	5.79	13.72	6.73	7.81	5.51	5.63	5.61	0.47	5.93	5.48	5.70	4.81	3.86	3.49	4.78	4.40	4.57	3.63
Shares Outstanding (Basic, Weighted)(shares)	2,407	2,407	2,534	2,625	2,632	2,633	2,645	2,682	2,692	2,737	2,772	2,815	2,809	2,753	2,736	2,751	2,760	2,803	2,883
Shares Outstanding (Diluted, Weighted)(shares)	2,429	2,429	2,560	2,664	2,674	2,671	2,684	2,729	2,745	2,789	2,813	2,864	2,877	2,813	2,775	2,789	2,789	2,836	2,911
Dividend per Share(per share)	5.14	4.91	4.70	4.45	4.19	3.98	3.75	3.54	3.32	3.15	2.95	2.76	2.59	2.40	2.25	2.11	1.93	1.80	1.62
EBITDA	–	–	–	–	–	–	–	–	–	–	–	25,485	20,516	18,621	16,923	20,639	19,356	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 28, 2026

Profitability, TTM

Gross margin: 67.9%
Operating margin: –
Net margin: 21.5%
Return on equity, FY2025: 35.0%

Financial strength

Current ratio: 1.09
Debt to equity: 0.58
Debt to assets: 24.4%
Cash to current liabilities: 37.2%

Valuation

P/E ratio: 29.4
Price to sales: 6.32
Price to book: 7.29
Dividend yield: 2.03%